Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENO1 | P06733 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678027 | 1.00 | ENO1 (0.46) | ENO1HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2824898 | 0.92 | HSD11B1 (0.46) | ENO1HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13662806 | 0.82 | HSD11B1 (0.39) | ENO1HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8038060 | 0.81 | HSD11B1 (0.51) | HSD11B1CYP3A4CYP2C9CYP2C19OPRM1 | |
| SCHEMBL4298912 | 0.79 | HSD11B1 (0.45) | HSD11B1CYP3A4CYP2C9CYP2C19OPRM1 | |
| SCHEMBL4100291 | 0.79 | HSD11B1 (0.45) | HSD11B1CYP3A4CYP2C9CYP2C19OPRM1 | |
| SCHEMBL4294143 | 0.79 | HSD11B1 (0.45) | HSD11B1CYP3A4CYP2C9CYP2C19OPRM1 | |
| SCHEMBL4304050 | 0.79 | HSD11B1 (0.45) | HSD11B1CYP3A4CYP2C9CYP2C19OPRM1 | |
| SCHEMBL4082787 | 0.79 | HSD11B1 (0.44) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4296589 | 0.78 | HSD11B1 (0.46) | HSD11B1CYP3A4CYP2C9CYP2C19PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270623-A1 | PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-1950211-A1 | PROCESS FOR PRODUCTION OF CINNAMAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270623-A1 | PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE | CBR1, H1-0, CBR3 | ENO1 1356/4885HSD11B1 495/4885CYP3A4 26/4885 |
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | ENO1 3234/4885HSD11B1 194/4885CYP3A4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.